Zobrazeno 1 - 5
of 5
pro vyhledávání: '"N. Ionichenok"'
Autor:
E. Panasyuk, Alexander Volkov, L. Denisov, M. Severinova, A. Ilyina, M. Cherkasova, A. Pchelintseva, A. Zhornyak, N. Ionichenok, A.V. Smirnov, I. Andrianova
Publikováno v:
Annals of the Rheumatic Diseases. 75:192.1-192
Background Monitoring of RA activity is important in daily practice and clinical trials, in particular for subjects receiving biologics. As a result, new imaging tools and more objective biomarkers of synovial inflammation and joint destruction have
Autor:
E. Panasyuk, Alexander Volkov, M. Severinova, M. Cherkasova, A. Zhornyak, L. Denisov, A. Pchelintseva, N. Ionichenok
Publikováno v:
Annals of the Rheumatic Diseases. 74:429.2-430
Background Etanercept (ETN) is effective anti-TNF treatment for rheumatoid arthritis (RA). Calprotectin (CP) and Matrix metalloproteinase-3 (MMP-3) are biomarkers associated with disease activity and joint destruction in RA. Ultrasonography (US) is a
Publikováno v:
Annals of the Rheumatic Diseases. 73:821.3-822
Background Calprotectin (CP) is potentially more sensitive biomarker of disease activity in rheumatoid arthritis (RA) than conventional acute-phase reactants because it directly reflects inflammation in the synovium rather than systemic inflammation.
Publikováno v:
Annals of the Rheumatic Diseases. 73:752.2-752
Background OA is a disease with articular cartilage degeneration, synovial and subchondral bone changes, meniscus and ligament pathologies. Bone marrow edema -like lesions (BMLs), with histologically represented bone damage, are predictors of cartila
Publikováno v:
Osteoarthritis and Cartilage. :S287
s / Osteoarthritis and Cartilage 22 (2014) S57–S489 S288 were analyzed using descriptive and bivariate test, parametric and no-parametric statistical tests were used. Results: We studied 72 patients, mean age 45 years 7.4, 83% female gender, educat